The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 22, 2023

Filed:

May. 27, 2022
Applicant:

Immatics Biotechnologies Gmbh, Tuebingen, DE;

Inventors:

Heiko Schuster, Tuebingen, DE;

Daniel Johannes Kowalewski, Tuebingen, DE;

Oliver Schoor, Tuebingen, DE;

Jens Fritsche, Tuebingen, DE;

Toni Weinschenk, Tuebingen, DE;

Harpreet Singh, Tuebingen, DE;

Gisela Schimmack, Tuebingen, DE;

Michael Roemer, Tuebingen, DE;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/725 (2006.01); C12N 5/0783 (2010.01); A61P 35/00 (2006.01); G01N 33/574 (2006.01); C07K 16/28 (2006.01); C07K 14/74 (2006.01); A61K 35/17 (2015.01); A61K 9/19 (2006.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01); G16B 25/10 (2019.01); C12N 15/115 (2010.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 9/19 (2013.01); A61K 35/17 (2013.01); A61K 39/001111 (2018.08); A61P 35/00 (2018.01); C07K 14/70539 (2013.01); C07K 16/2809 (2013.01); C07K 16/2833 (2013.01); C12N 5/0638 (2013.01); C12N 15/115 (2013.01); G01N 33/57492 (2013.01); G16B 25/10 (2019.02); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C12N 2310/16 (2013.01);
Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.


Find Patent Forward Citations

Loading…